American Journal of Biotechnology and Bioscience


A novel plant genome editing CRISPR/Cas9 System: To modify stress tolerance responses in plants

The plant genome modification by Crispr/Cas9 system is gaining ground. In molecular biology, the use of this indispensable tool works on the basis of target recognition due to the existence of a short protospacer adjacent motif (PAM) that is complementary to the desired strand. The components of the genome-editing tool are guide RNA, Cas9 protein. The mechanistic nature of CRISPR/ Cas9 technology i.e. adaptation, expression and interference lead the desirable mutations in the crop plants. According to the need one can use the different types of programmable DNA targeting and editing platform type. The goal of this review is to provide an idea of the production of stress-tolerant crops. The molecular perception from structural and mechanistic research grant a groundwork for rational engineering for the production of plants that can withstand different kinds of stress.

Analysis of traditional house hold alcoholic beverage to processing plant level production

Alcohol use is part of many cultural, religious and social practices, and provides perceived pleasure to many users. The aim of this project was to develop mini scale alcohol production, which would be very useful for those who focus for many developing countries including Ethiopia, developing this project have been valuable for such sector for those who had an idea to develop new alcoholic beverage project professionals. The paper tried to evaluate the economic performance of minimum level alcohol production, grow to in terms of productivity, profitability, capacity utilization, marketing and the socio-economic contribution of the project. Those, the total capital investments found from this study analysis estimated to be total 34, 673,529.41 birr and the total production cost is 4520833.3birr/yr. The Company will get a net income of 1,376,650,000 birr/year. The repayment for the investment cost will be paid off over the next 4.6 years. The project provides for efficient utilization of the existing resource, technological advancement, managerial efficiency and incentives to upgrade traditional beverages to large production process scales.

Symptoms, Gene Analysis, Diagnosis and Treatment of Neurofibromatosis type 1 (NF1) syndrome

Neurofibromatosis type 1 (NF1) is an autosomal predominant, mucocutaneous and inclination disorder. They include it in the development of benign and malignant tumors. Hereditary change in NF1 prompts changes in the outflow of cytoplasmic protein. 90% of all cases represent NF1 in neurofibromatosis. children tainted with NF1, they distinguish them inside a year.NF1 Patients ordinarily experience the ill effects of the café au laitt, freckling, and skeletal dysplasia. The GTPase actuating protein goes about as the principal job in NF1 quality, which fills in as a negative controlled by authoritative with the RAS protein. The neurofibromatosis type 1 quality is a 287-kilo premise of chromosome 17q11.2. In NF1 patients, the dermatologists distinguished the basic cutaneous highlights. Cutaneous neurofibroma has a variable pace of development during life expectancy. The threatening fringe nerve sheath tumor is plexiform neurofibromas. Palpebral plexiform neurofibroma is mono-sidelong. We have analyzed inherent dysplasia real criteria for NF1. The more exact technique to analyze NF1 in the patient is radiological indicative. An entire body MRI can test the interior nerve sheath tumor. They have announced that the research center analytic is extremely troublesome; However , it has done the RNA and ELISA tests somewhat. The treatment of NF1 patients is exceptionally troublesome because of the adequacy of the organ of the body. There is a biopsy, medical procedure, and radiotherapy performed for NF1 patients.

Affordability Issues of Biotech Drugs in low- and middle-income countries (LMICs)

As indicated by World Bank publication Disease Control Priorities: Improving Health and Reducing Poverty (third edition, 2017), about 20% all out health use universally originated from out-of-pocket payments in 2014. The equivalent was about 40% all out health use for low-income countries, 56% for lower-middle-income countries, and 30% for upper-middle-income countries (WHO, 2016). 33% of the world’s populace needs opportune access to quality-guaranteed medicines while assessments demonstrate that in any event 10% of medicine in low-and middle-income countries (LMICs) are substandard or distorted, costing roughly US$ 31 billion every year (Global Health, 2018). Shockingly, 80% of worldwide cardiovascular passings happen in LMICs which is (halfway) because of the absence of access to healthcare including talented HR, equipped offices and medicines (Global status report on noncommunicable diseases, WHO, 2010). Cost of drugs, antibodies, and diagnostics is a noteworthy weight in LMICs round the globe. Cost of biotech drugs are much higher because of surprising expense caused by the pharmaceutical organizations for clinical preliminary. Biotech drugs have totally changed the administration of a few diseases, including malignant growth and immune system diseases. Albeit essential yet their affordability is as yet a consuming issue, particularly in LMICs.

Novel urease inhibitor

Urease, also known as urea amide hydrolase, contains two metal nickel ion active centers that catalyze the decomposition of urea to ammonia and carbon dioxide. Urease is widely found in nature, including plants, animals, and microorganisms, and greatly affects the utilization of nitrogen-containing nutrients by plants and animals. At the same time, its content can also affect the normal physiological metabolism of microorganisms, which in turn affects the survival rate of microorganisms. It can be seen that the role of urease inhibitors is very important. Urease inhibitors, such substances, can affect or even inhibit the activity of urease by direct or indirect means. Guided by computer-aided drug design, the team developed two new urease inhibitors, which are low-cost, non-toxic to plants, animals and humans, and environmentally friendly urease inhibitors. After experimentally measuring the activity of urease inhibitors, the two urease inhibitors have stronger inhibition ability than the widely used acetohydroxamic acid on the market.

Dr. Jamunarani Veeraraghavan
Baylor College of Medicine, One Baylor Plaza, Houston, Texas

Dr. Moustafa M. Zeitoun
Professor, Department of Animal Production, Faculty of Agriculture, University of Alexandria, El-Shatby, Alexandria, Egypt; Department of Animal Production and Breeding, College of Agriculture and Veterinary Medicine, Qassim University

Dr. K.S. Kanwal
Scientist-C, G.B. Pant National Institute of Himalayan Environment and Sustainable Development, North East Unit, Vivek Vihar, Itanagar-791113, Arunachal Pradesh, India

Dr. Surabhi Mishra
Resarch Scientist, Dept. of Microbiology, University of Iowa, IA – 52242

Dr. Miriam-Rose Menezes
UTHealth Science Center Houston

Dr. Yan Zhou
Harvard Medical School, Boston, USA

Dr. Richa Madan Lomash
Research Fellow, Receptor Biology Unit (NINDS), NIH, Bethesda (MD), USA

Dr. FRANCESCA DIOMEDE
Department of Medical, Oral and Biotechnological Sciences, University G. d’Annunzio, Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti (IT)

Dr. Sirisha Adamala
Assistant Professor, Department of Applied Engineering, Vignan’s University

Dr. Abhishek Naik
Area Manager, Technology development department

Dr. Moustafa Mohamed Sabry Bakry
Plant Protection Research Institute Agricultural Research Center, Giza, Egypt

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1.R. M. AKPLOGAN, G. H. T. CACAÏ, S. S. HOUEDJISSIN, V.MÈGNIKPA, C. AHANHANZ.Influence of mercuric chloride and sodium hypochlorite on apical and axillary buds regeneration of Colocasia esculenta in tissue culture. American Journal of Biotechnology and Bioscience, 2018; 2:10. DOI: 10.28933/ajbb-2018-11-1908 
2.Bienvenu T. Badou, Arnaud Agbidinoukoun, Gilles T.H. Cacaï, René C. Dossoukpèvi and Corneille Ahanhanzo. Effects of system benzylaminopurine-adenine sulphate in combination with naphthalene acetic on in vitro regeneration and proliferation of pineapple (Ananas comosus (L.) Mill var. comosus). American Journal of Biotechnology and Bioscience, 2018; 2:9.. DOI: 10.28933/ajbb-2018-05-1801 

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fee: The authors will be contacted about the publication fee after a manuscript have been accepted.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

Open Access
American Journal of Biotechnology and Bioscience is a peer reviewed open access journal publishing research manuscripts, review articles, case reports, editorials, letters to the editor in Biotechnology and Bioscience (Indexing information).

Peer Review
To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication
Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team
Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions shortly.

American Journal of Biotechnology and Bioscience

Loading